GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » Peter Lynch Fair Value

Vivani Medical (Vivani Medical) Peter Lynch Fair Value : N/A (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Vivani Medical's Peter Lynch Fair Value or its related term are showing as below:



VANI's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.605
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Vivani Medical Peter Lynch Fair Value Historical Data

The historical data trend for Vivani Medical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical Peter Lynch Fair Value Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
- - - -

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivani Medical's Peter Lynch Fair Value

For the Biotechnology subindustry, Vivani Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivani Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Vivani Medical's Price-to-Peter-Lynch-Fair-Value falls into.



Vivani Medical Peter Lynch Fair Value Calculation

Vivani Medical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.5
=N/A

Vivani Medical's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-0.50.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Vivani Medical  (NAS:VANI) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Vivani Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=1.62/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivani Medical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Vivani Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical (Vivani Medical) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 280, Emeryville, CA, USA, 94608
Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
Executives
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342